title: Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial.
abstract: OBJECTIVE
  To evaluate the long-term efficacy of etanercept for the management of hidradenitis suppurativa.
  
  
  METHODS
  Analysis was based on the long-term follow-up (weeks 24-144) of 10 patients enrolled in a prospective open-label phase II study; etanercept was initially administered subcutaneously 50 mg once weekly for 12 weeks in 10 patients. Disease recurrence and the need to restart etanercept were recorded.
  
  
  RESULTS
  Three patients did not report any disease recurrence. A second course of treatment with etanercept was needed in seven patients. Favourable responses were found in five; two patients failed treatment.
  
  
  CONCLUSIONS
  The first treatment course achieved long-term disease remission in almost one-third of patients. The remaining needed a second treatment course but even in that case, their disease severity at restart was significantly lower compared with baseline.
authors.forename: Aimilia
authors.initials: A
authors.lastname: Pelekanou
authors.forename: Theodora
authors.initials: T
authors.lastname: Kanni
authors.forename: Athina
authors.initials: A
authors.lastname: Savva
authors.forename: Maria
authors.initials: M
authors.lastname: Mouktaroudi
authors.forename: Maria
authors.initials: M
authors.lastname: Raftogiannis
authors.forename: Antigone
authors.initials: A
authors.lastname: Kotsaki
authors.forename: Evangelos J
authors.initials: EJ
authors.lastname: Giamarellos-Bourboulis
mesh_terms: D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D017497:Hidradenitis Suppurativa / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept